Would you use trastuzumab with chemotherapy in a patient with metastatic gastric cancer that is HER2 negative but ERBB3 positive?
Would you use this combination in frontline vs later lines of therapy ?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on
No, there are clearly no validated data for this and I do not have any anecdotal experience to suggest benefit.
Such a patient should be referred for studies of pan-ErBB inhibitors, e.g. afatinib or neratinib.
Join for free or sign in to see the full answer